On December 1st, the legal landscape of the pharmaceutical and biotech industry will be thrust into the spotlight in New York, NY. A major Hybrid Event: Developments in Pharmaceutical and Biotech Patent Law 2023 is turning heads and garnering attention from legal professionals overseeing corporate law in major corporations and law firms worldwide.
2023 marks a year of considerable shift in the health care landscape. Influential new federal legislation has been introduced to target Pharmacy Benefit Managers (PBMs) and Medicare continues its advancement in negotiating drug prices. Besides, there has been noteworthy litigation concerning access to mifepristone and other women’s healthcare, which is prompting significant dialogues throughout the industry. Furthermore, this year has seen the expansion of Department of Justice (DOJ) enforcement interest in digital health.
These dimensions are not merely dotting the i’s and crossing the t’s of the industry’s legal landscape; they are architecting new terrain and bringing unexplored challenges to those working within the sector. The heath care industry is changing dramatically, and those at the forefront are tasked with maintaining a responsive and well-informed perspective.
The hybrid event is hosted by the Practising Law Institute (PLI), an organization renowned for its collective of skilled health care lawyers, in-house counsel, and government regulators. The event promises to facilitate an examination of the current state of pharmaceutical and biotech patent law, providing attendees with an opportunity to deepen their understanding of these critical developments.
This, coupled with an opportunity to interact with PLI’s expert faculty, indeed makes this hybrid event an unmissable occasion for practicing lawyers, legal advisors, and anyone else vested in the intricate and ever-evolving web of laws governing the pharmaceutical and biotechnology industry.